INFOGRAPHIC: PCSK9 inhibitors alirocumab and evolocumab side-by-side
This article was originally published in Scrip
Executive Summary
Clinical trial results to date for the PCSK9 inhibitors evolocumab from Amgen and alirocumab from Sanofi and Regeneron Pharmaceuticals have been quite similar in patients with hypercholesterolemia, or high cholesterol, across several studies even though no two study designs are exactly alike.